MedTrace Logo

PoC in Rheumatoid Arthritis With Methotrexate

NCT00605735 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 121

Last updated 2015-10-12

No results posted yet for this study

Summary

The purpose of this study is to find out if 300 mg of BMS-582949 given once daily will be more effective than placebo after 12 weeks of treatment in subjects with rheumatoid arthritis who are also taking methotrexate

Conditions

  • Rheumatoid Arthritis, NOS

Interventions

DRUG

BMS-582949

Tablets, Oral, 300 mg, once daily, 12 weeks

DRUG

Placebo

Tablets, Oral, placebo, once daily, 12 weeks

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2009-08-31
Completion
2009-09-30

Countries

  • United States
  • Argentina
  • Czechia
  • France
  • Mexico
  • South Korea
  • Spain
  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00605735 on ClinicalTrials.gov